Welcome to our dedicated page for Inmed Pharmaceuticals SEC filings (Ticker: INM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InMed Pharmaceuticals Inc. filings document the regulatory record of a British Columbia pharmaceutical issuer with common shares listed on Nasdaq under INM. Its disclosures cover small-molecule drug development programs targeting CB1 and CB2 receptors, including INM-901 for Alzheimer's disease and programs in ocular and dermatological indications.
Recent filings include Current Reports on Form 8-K for financial results and business updates, material definitive agreements involving preferred investment options, at-the-market offering documentation, Nasdaq continued-listing compliance, shareholder voting matters, and exit or disposal activities related to BayMedica. The company's formal reports also address risk factors, capital structure, governance, and clinical or regulatory disclosures.
InMed Pharmaceuticals Inc. outlines its 2026 pharmaceutical development outlook, focusing on two small molecule drug candidates targeting CB1/CB2 receptors. The lead program, INM-901 for Alzheimer’s disease, has generated preclinical data suggesting anti-neuroinflammatory, neuroprotective and neuritogenic effects, along with oral bioavailability and supportive molecular findings.
The company plans a pre-IND meeting with the U.S. Food and Drug Administration for INM-901 in Q3 2026 and aims to complete IND-enabling studies ahead of a targeted Phase 1 clinical trial start in 2027. A second candidate, INM-089 for dry age-related macular degeneration, is progressing through preclinical work, with a planned FDA pre-IND meeting in Q4 2026.
InMed Pharmaceuticals is winding down the commercial operations of its BayMedica subsidiary in response to expected U.S. legislation (H.R. 5371) that would materially harm BayMedica’s rare cannabinoid business. BayMedica is the company’s only revenue-generating commercial segment.
The wind down is expected to be substantially completed by June 30, 2026, with operations continuing in the interim to sell existing products. BayMedica anticipates severance and employee-related costs of about $550,000 and other related expenditures of about $120,000, partly offset by remaining product profits.
After the exit, InMed plans to focus exclusively on its pharmaceutical pipeline, including drug candidates INM-901 for Alzheimer’s disease and INM-089 for dry age-related macular degeneration. Unaudited pro forma financials reclassify BayMedica’s business as discontinued operations.
InMed Pharmaceuticals reported second quarter fiscal 2026 results and updated progress across its neurology and ophthalmology drug pipeline. BayMedica commercial revenue was $0.8 million, down from $1.1 million a year earlier, mainly due to pending U.S. legislation that may restrict rare, non-intoxicating cannabinoids.
The company recorded a quarterly net loss of $2.0 million, improving from a $2.6 million loss last year, as research and development expenses fell to $0.6 million from $0.9 million and general and administrative costs eased slightly. As of December 31, 2025, cash, cash equivalents and short-term investments totaled $7.0 million, down from $11.1 million at fiscal year-end, and are expected to fund operations into the fourth quarter of calendar 2026.
Lead candidate -901 for Alzheimer’s disease showed robust oral bioavailability and no adverse neurological effects in large-animal studies, supporting plans for GLP-enabling work and an IND submission. Dry AMD candidate -089 continues to deliver functional and pathological improvements in preclinical models. However, U.S. Act H.R. 5371 could prohibit key BayMedica products from November 12, 2026, potentially forcing inventory write-offs or even discontinuation of BayMedica’s business, which the company warns would have a material adverse effect on its operations and financial condition.
InMed Pharmaceuticals Inc. reported lower commercial revenue and continuing losses for the three and six months ended December 31, 2025, while flagging substantial doubt about its ability to continue as a going concern. BayMedica’s rare‑cannabinoid business faces potential prohibition under new U.S. legislation, which could force inventory write‑offs or exit. The company also highlighted an arbitration over a technology license where the counterparty is seeking significant royalty payments, noting that an unfavorable outcome could materially harm its financial condition and BayMedica’s operations.
Sabby Volatility Warrant Master Fund, Ltd., together with Sabby Management, LLC and Hal Mintz, reports beneficial ownership of 280,138 shares of InMed Pharmaceuticals Inc. common stock, representing 9.9% of the class as of 12/31/2025. The group has shared power to vote and dispose of these shares, with no sole voting or dispositive power reported by any party.
The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of InMed, and that their holdings are not connected with any control-related transaction, other than activities solely in connection with a nomination under the specified proxy rule.
InMed Pharmaceuticals Inc. reported the results of its 2025 Annual General and Special Meeting of Shareholders held on December 17, 2025. Shareholders elected five directors – Eric A. Adams, Andrew Hull, Nicole Lemerond, Neil Klompas and John Bathery – each receiving between 81.94% and 82.11% of votes cast in favor.
Shareholders also approved the appointment of CBIZ CPAs P.C as InMed’s independent registered public accounting firm until the 2026 annual meeting, with 78.84% of votes for and 21.16% abstaining. A key item, the SEPA Share Issuance Proposal, passed with 65.89% support and 34.11% against, authorizing the potential issuance of 20% or more of the company’s common shares outstanding as of December 13, 2024 under a Standby Equity Purchase Agreement with YA II PN, Ltd., in accordance with Nasdaq Listing Rules 5635(d) and 5635(b). No other matters were voted on.
InMed Pharmaceuticals Inc. reported that one of its directors had an employee stock option position expire involving 14 derivative securities on December 15, 2025. These employee stock options related to 14 common shares and carried a U.S. dollar exercise price of $1,397.97, converted from a Canadian dollar exercise price of C$1,925.00 at an exchange rate of C$1.3770 = US$1.00. After this transaction, the director beneficially owned 961 derivative securities with direct ownership.
InMed Pharmaceuticals Inc. reported an insider derivatives transaction involving its President & CEO and Director, Eric A. Adams, dated 12/15/2025. The filing shows an employee stock option labeled "Employee Stock Option (Expiration)" tied to 250 derivative securities related to the company's common shares.
The option carried a U.S. dollar exercise price of $1,397.97 per the form, calculated from a Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00. Following this reported transaction, Adams directly beneficially owns 14,050 derivative securities.
InMed Pharmaceuticals Inc.'s Chief Operating Officer, as a single reporting person, filed a Form 4 detailing an insider derivatives transaction with the company.
On 12/15/2025, an employee stock option labeled as an expiration and linked to 60 common shares was reported, with a US$1,397.97 exercise price, converted from a C$1,925.00 exercise price using an exchange rate of C$1.3770 = $US1.00. After this transaction, 7,445 derivative securities were reported as beneficially owned on a direct basis.
InMed Pharmaceuticals Inc. reported an insider transaction by officer Eric C. Hsu, who serves as Sr. VP, Pre-Clinical Res/Dev, involving employee stock options dated 12/15/2025.
The filing shows an employee stock option labeled as an expiration covering 70 common shares, with an exercise price of $1,397.97, converted from a Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00. The option had an exercisable date of 12/16/2020 and an expiration date of 12/15/2025. Following this transaction, Hsu beneficially owned 5,280 derivative securities, held directly.